{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:29:14Z","timestamp":1787315354297,"version":"build-2736575974"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010846","name":"Health and Family Planning Commission of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010846","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010846","name":"Health and Family Planning Commission of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010846","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Behcet\u2019s disease (BD) is a chronic immune disease that involves multiple systems. As the pathogenesis of BD is not clear, and new treatments are needed, we used bioinformatics to identify potential drugs and validated them in mouse models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Behcet\u2019s disease-related target genes and proteins were screened in the PubMed and UVEOGENE databases. The biological functions and pathways of the target genes were analyzed in detail by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. A protein-protein interaction (PPI) network was constructed by the STRING database, and hub genes were identified by the Cytoscape plug-in CytoHubba. Gene-drug interactions were identified from the DGIdb database. Experimental autoimmune uveitis (EAU) mice were used as an animal model for drug validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 249 target genes and proteins with significant differences in BD were screened, and the results of functional enrichment analysis suggested that these genes and proteins were more located on the cell membrane, involved in regulating the production of cytokines and affecting the activity of cytokines. They mainly regulated \u201cCytokine- Cytokine receptor interaction\u201d, \u201cInflammatory bowel disease (IBD)\u201d and \u201cIL-17 signaling Pathway\u201d. In addition, 10 hub genes were obtained through PPI network construction and CytoHubba analysis, among which the top 3 hub genes were closely related to BD. The DGIdb analysis enriched seven drugs acting together on the top 3 hub genes, four of which were confirmed for the treatment of BD or its complications. There is no evidence in the research to support the results in omeprazole, rabeprazole, and celastrol. However, animal experiments showed that rabeprazole and celastrol reduced anterior chamber inflammation and retinal inflammation in EAU mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The functional analysis of genes and proteins related to BD, identification of hub genes, and validation of potential drugs provide new insights into the disease mechanism and potential for the treatment of BD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.895869","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:51:01Z","timestamp":1655772661000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Candidate Drugs Screening for Behcet\u2019s Disease Based on Bioinformatics Analysis and Mouse Experiments"],"prefix":"10.3389","volume":"13","author":[{"given":"Qinyun","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chujun","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.02.011","article-title":"Behcet's Disease\u2013A Contemporary Review","volume":"32","author":"Mendes","year":"2009","journal-title":"J Autoimmun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00665","article-title":"Immunopathogenesis of Behcet's Disease","volume":"10","author":"Tong","year":"2019","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.11.026","article-title":"New Insights Into the Pathogenesis of Behcet's Disease","volume":"11","author":"Pineton de Chambrun","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.9.1175","article-title":"Behcet's Disease: From Hippocrates to the Third Millennium","volume":"87","author":"Verity","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.berh.2004.02.008","article-title":"Behcet's Disease","volume":"18","author":"Marshall","year":"2004","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92643-V","article-title":"Criteria for Diagnosis of Behcet's Disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2007.09.002","article-title":"Behcet's Disease: Ocular Effects and Treatment","volume":"27","author":"Deuter","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2019.02.002","article-title":"Eye and Behcet's Disease","volume":"42","author":"Ksiaa","year":"2019","journal-title":"J Fr Ophtalmol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The Long-Term Mortality and Morbidity of Behcet Syndrome: A 2-Decade Outcome Survey of 387 Patients Followed at a Dedicated Center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Med (Baltimore)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in Patients With Active Noninfectious Uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key242","article-title":"Management of Major Organ Involvement of Behcet's Syndrome: A Systematic Review for Update of the EULAR Recommendations","volume":"57","author":"Ozguler","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13381","article-title":"Behcet's Disease: A Comprehensive Review With a Focus on Epidemiology, Etiology and Clinical Features, and Management of Mucocutaneous Lesions","volume":"43","author":"Alpsoy","year":"2016","journal-title":"J Dermatol"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.140.5.1490","article-title":"A New Model of Autoimmune Disease. Experimental Autoimmune Uveoretinitis Induced in Mice With Two Different Retinal Antigens","volume":"140","author":"Caspi","year":"1988","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23702","article-title":"UVEOGENE: An SNP Database for Investigations on Genetic Factors Associated With Uveitis and Their Relationship With Other Systemic Autoimmune Diseases","volume":"40","author":"Wang","year":"2019","journal-title":"Hum Mutat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.587443","article-title":"Integrated Analysis of Key Pathways and Drug Targets Associated With Vogt-Koyanagi-Harada Disease","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1143","article-title":"DGIdb 3.0: A Redesign and Expansion of the Drug-Gene Interaction Database","volume":"46","author":"Cotto","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-13323","article-title":"Activation of Liver X Receptor Alleviates Ocular Inflammation in Experimental Autoimmune Uveitis","volume":"55","author":"Yang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-019-01219-x","article-title":"Celastrol Suppresses Experimental Autoimmune Encephalomyelitis via MAPK\/SGK1-Regulated Mediators of Autoimmune Pathology","volume":"68","author":"Venkatesha","year":"2019","journal-title":"Inflammation Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00372.2003","article-title":"Monocyte Chemotactic Protein-1 Regulates Leukocyte Recruitment During Gastric Ulcer Recurrence Induced by Tumor Necrosis Factor-Alpha","volume":"287","author":"Watanabe","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000075698","article-title":"Increased Expression of Cytokines and Adhesion Molecules in Rat Chronic Esophagitis","volume":"68","author":"Hamaguchi","year":"2003","journal-title":"Digestion"},{"key":"B21","doi-asserted-by":"publisher","first-page":"15.6","DOI":"10.1002\/0471142735.im1506s53","article-title":"Experimental Autoimmune Uveoretinitis in the Rat and Mouse","volume":"15","author":"Caspi","year":"2003","journal-title":"Curr Protoc Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa086","article-title":"Management of Behcet's Syndrome","volume":"59","author":"Karadag","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e10049","DOI":"10.7759\/cureus.10049","article-title":"Transvenous Catheter-Based Thrombolysis With Continuous Tissue Plasminogen Activator Infusion for Refractory Thrombosis in a Patient With Behcet's Disease","volume":"12","author":"Arif","year":"2020","journal-title":"Cureus"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.10.024","article-title":"Real-World Efficacy of Adalimumab and Infliximab for Refractory Intestinal Behcet's Disease","volume":"51","author":"Sugimura","year":"2019","journal-title":"Dig Liver Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating Inflammation by Blocking Interleukin-1 in Humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"451675","DOI":"10.1155\/2015\/451675","article-title":"Mucocutaneous Involvement in Behcet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives","volume":"2015","author":"Rotondo","year":"2015","journal-title":"Mediators Inflamm"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/1043-4666(92)90028-p","article-title":"The Role of Cytokines in the Pathogenesis of Inflammatory Eye Disease","volume":"4","author":"Wakefield","year":"1992","journal-title":"Cytokine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2008.10.007","article-title":"Interleukin-6 in Neuro-Behcet's Disease: Association With Disease Subsets and Long-Term Outcome","volume":"44","author":"Akman-Demir","year":"2008","journal-title":"Cytokine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1390","article-title":"Upregulated IL-23 and IL-17 in Behcet Patients With Active Uveitis","volume":"49","author":"Chi","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.02.002","article-title":"Biotherapies in Inflammatory Ocular Disorders: Interferons, Immunoglobulins, Monoclonal Antibodies","volume":"12","author":"Saadoun","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4049-7","article-title":"Correlation Between IL-17a\/F, IL-23, IL-35 and IL-12\/-23 (P40) Levels in Peripheral Blood Lymphocyte Cultures and Disease Activity in Behcet's Patients","volume":"37","author":"Sonmez","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030896","article-title":"Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041257","article-title":"IL-23 Drives a Pathogenic T Cell Population That Induces Autoimmune Inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.imlet.2016.12.001","article-title":"An Elevated Pro-Inflammatory Cytokines Profile in Behcet's Disease: A Multiplex Analysis","volume":"186","author":"Gholijani","year":"2017","journal-title":"Immunol Lett"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/396204","article-title":"Proinflammatory Cytokines and C-Reactive Protein in Uveitis Associated With Behcet's Disease","author":"Mesquida","year":"2014","journal-title":"Mediators Inflamm"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/03009740600905380","article-title":"Expression of Cytokines, Chemokines, and Chemokine Receptors in Oral Ulcers of Patients With Behcet's Disease (BD) and Recurrent Aphthous Stomatitis is Th1-Associated, Although Th2-Association is Also Observed in Patients With Bd","volume":"35","author":"Dalghous","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.01.014","article-title":"Cytokine Profiles in Aqueous Humor of Patients With Different Clinical Entities of Endogenous Uveitis","volume":"139","author":"El-Asrar","year":"2011","journal-title":"Clin Immunol"},{"key":"B38","article-title":"A Th1 But Not a Th17 Response is Present in the Gastrointestinal Involvement of Behcet's Disease","volume":"28","author":"Ferrante","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor Necrosis Factor Antagonist Mechanisms of Action: A Comprehensive Review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1328496","article-title":"Management of Severe Complications in Behcet's Disease With TNF Inhibitors","volume":"17","author":"Desbois","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-005-0040-0","article-title":"Synovial Proinflammatory Cytokines and Their Correlation With Matrix Metalloproteinase-3 Expression in Behcet's Disease. Does Interleukin-1beta Play a Major Role in Behcet's Synovitis","volume":"26","author":"Pay","year":"2006","journal-title":"Rheumatol Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1159\/000358125","article-title":"Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behcet's Disease: A Case Series","volume":"228","author":"Vitale","year":"2014","journal-title":"Dermatology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1beta-Regulating Antibody XOMA 052 (Gevokizumab) in the Treatment of Acute Exacerbations of Resistant Uveitis of Behcet's Disease: An Open-Label Pilot Study","volume":"71","author":"Gul","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra Treatment in Drug-Resistant Behcet's Disease: A Case Series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.autrev.2011.12.005","article-title":"Cytokines and Behcet's Disease","volume":"11","author":"Zhou","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B47","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ng.625","article-title":"Genome-Wide Association Study Identifies Variants in the MHC Class I, IL10, and IL23R-IL12RB2 Regions Associated With Behcet's Disease","volume":"42","author":"Remmers","year":"2010","journal-title":"Nat Genet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/ng.624","article-title":"Genome-Wide Association Studies Identify IL23R-IL12RB2 and IL10 as Behcet's Disease Susceptibility Loci","volume":"42","author":"Mizuki","year":"2010","journal-title":"Nat Genet"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.02.022","article-title":"Effective Treatment of Rat Adjuvant-Induced Arthritis by Celastrol","volume":"11","author":"Cascao","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S27860","article-title":"Celastrol Nanoparticles Inhibit Corneal Neovascularization Induced by Suturing in Rats","volume":"7","author":"Li","year":"2012","journal-title":"Int J Nanomedicine"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1039\/c5mb00864f","article-title":"A Lipidomics Investigation Into the Intervention of Celastrol in Experimental Colitis","volume":"12","author":"Wang","year":"2016","journal-title":"Mol Biosyst"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3390\/pharmaceutics13122005","article-title":"Colonic Delivery of Celastrol-Loaded Layer-By-Layer Liposomes With Pectin\/Trimethylated Chitosan Coating to Enhance Its Anti-Ulcerative Colitis Effects","volume":"13","author":"Xian","year":"2021","journal-title":"Pharmaceutics"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00044","article-title":"Celastrol Attenuates Multiple Sclerosis and Optic Neuritis in an Experimental Autoimmune Encephalomyelitis Model","volume":"8","author":"Yang","year":"2017","journal-title":"Front Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S323208","article-title":"Celastrol Niosome Hydrogel Has Anti-Inflammatory Effect on Skin Keratinocytes and Circulation Without Systemic Drug Exposure in Psoriasis Mice","volume":"16","author":"Qiu","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.199117","article-title":"Efficacy of Proton Pump Inhibitors for Patients With Duodenal Ulcers: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials","volume":"23","author":"Hu","year":"2017","journal-title":"Saudi J Gastroenterol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.032","article-title":"Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives","volume":"146","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-012-0395-2","article-title":"Do Proton Pump Inhibitors Protect Against Cancer Progression in GERD","volume":"43","author":"Miyashita","year":"2013","journal-title":"Surg Today"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1038\/cddis.2016.218","article-title":"Proton Pump Inhibitors Protect Mice From Acute Systemic Inflammation and Induce Long-Term Cross-Tolerance","volume":"7","author":"Balza","year":"2016","journal-title":"Cell Death Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-006-6056-4","article-title":"Molecular Mechanisms Involved in Anti-Inflammatory Effects of Proton Pump Inhibitors","volume":"55","author":"Handa","year":"2006","journal-title":"Inflammation Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40360-021-00509-7","article-title":"Rabeprazole Inhibits Inflammatory Reaction by Inhibition of Cell Pyroptosis in Gastric Epithelial Cells","volume":"22","author":"Xie","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000001897","article-title":"Omeprazole Increases Survival Through the Inhibition of Inflammatory Mediaters in Two Rat Sepsis Models","volume":"57","author":"Kotsuka","year":"2022","journal-title":"Shock"},{"key":"B62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12950-021-00284-6","article-title":"Esomeprazole Attenuates Inflammatory and Fibrotic Response in Lung Cells Through the MAPK\/Nrf2\/HO1 Pathway","volume":"18","author":"Ebrahimpour","year":"2021","journal-title":"J Inflammation (Lond)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-2803.201900000-49","article-title":"Evaluation of Psoriasis Treatment With Esomeprazole - A Pilot Study","volume":"56","author":"Bafutto","year":"2019","journal-title":"Arq Gastroenterol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s40168-018-0520-6","article-title":"A Metagenomic Study of the Gut Microbiome in Behcet's Disease","volume":"6","author":"Ye","year":"2018","journal-title":"Microbiome"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-005-9035-7","article-title":"Monitoring Cytochrome P-450 Activity During Rabeprazole Treatment in Patients With Gastresophageal Reflux Disease","volume":"51","author":"Giannini","year":"2006","journal-title":"Dig Dis Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.895869\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T16:52:25Z","timestamp":1675875145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.895869\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2022.895869"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.895869","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"article-number":"895869"}}